232 related articles for article (PubMed ID: 6640524)
1. Lysis of fresh natural killer-resistant tumor cells by lectin-activated syngeneic and allogeneic murine splenocytes.
Mazumder A; Rosenstein M; Rosenberg SA
Cancer Res; 1983 Dec; 43(12 Pt 1):5729-34. PubMed ID: 6640524
[TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
LeFor AT; Eisenthal A; Rosenberg SA
J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
[TBL] [Abstract][Full Text] [Related]
4. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
5. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
6. LY-2+ effectors cytotoxic for syngeneic tumor cells: generation by allogeneic stimulation and by supernatants from mixed leukocyte cultures.
Hurrell SM; Zarling JM
J Immunol; 1983 Aug; 131(2):1017-23. PubMed ID: 6223084
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
Vujanovic NL; Herberman RB; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
[TBL] [Abstract][Full Text] [Related]
8. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
[TBL] [Abstract][Full Text] [Related]
9. [The in vitro antitumor effectiveness of murine lymphokine-activated killer (LAK) cells induced by recombinant IL-2].
Okamoto Y; Shimizu K; Miyao Y; Ushio Y; Matsui Y; Hayakawa T; Tsuda N; Mogami H
No To Shinkei; 1986 Mar; 38(3):233-7. PubMed ID: 3486667
[TBL] [Abstract][Full Text] [Related]
10. Rat natural killer cell activity against lymphoid and nonlymphoid tumor cells and normal rat cell lines.
Rees RC; Reynolds CW; Herberman RB
Cancer Res; 1983 Sep; 43(9):4248-52. PubMed ID: 6871862
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin.
Mazumder A; Grimm EA; Rosenberg SA
J Immunol; 1983 Feb; 130(2):958-64. PubMed ID: 6848602
[TBL] [Abstract][Full Text] [Related]
12. Requirements for T cells in alloantigen-induced generation of non-T cell-mediated cytotoxicity against syngeneic mouse sarcoma cells.
Paciucci PA; Macphail S; Bach FH; Zarling JM
J Immunol; 1980 Jul; 125(1):36-9. PubMed ID: 6155401
[TBL] [Abstract][Full Text] [Related]
13. Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice.
Andriole GL; Mulé JJ; Hansen CT; Linehan WM; Rosenberg SA
J Immunol; 1985 Nov; 135(5):2911-3. PubMed ID: 3876368
[TBL] [Abstract][Full Text] [Related]
14. Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins.
Mazumder A; Grimm EA; Zhang HZ; Rosenberg SA
Cancer Res; 1982 Mar; 42(3):913-8. PubMed ID: 7059990
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated antigenic differences between the primary and the descendant metastatic tumor cell populations.
Gorelik E; Fogel M; Segal S; Feldman M
J Supramol Struct; 1979; 12(3):385-402. PubMed ID: 94933
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
[TBL] [Abstract][Full Text] [Related]
17. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
Sensi ML; Parenza M; Parmiani G
J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
19. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432.
Uchida A; Micksche M
J Natl Cancer Inst; 1983 Oct; 71(4):673-80. PubMed ID: 6413742
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte-mediated cytotoxicity against allogeneic tumour cells. IV. Fine specificity mapping and characterization of concanavalin A-activated cytotoxic effector lymphocytes.
Waterfield JD; Nixon DF; Mair MG
Immunology; 1981 Dec; 44(4):685-93. PubMed ID: 6797935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
